Have you or your loved ones been diagnosed with advanced or metastatic solid tumors?

You may be eligible to participate in a advanced or metastatic solid tumors clinical trial.

Have you or your loved ones been diagnosed with advanced or metastatic solid tumors? You may be eligible to participate in a advanced or metastatic solid tumors clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Advanced or Metastatic Solid Tumors Clinical Trial
NCT03316638 | Phase 1 phase 2 | Interventional

Have you or your loved ones been diagnosed with advanced or metastatic solid tumors?

You may be eligible to participate in a advanced or metastatic solid tumors clinical trial.

Have you or your loved ones been diagnosed with advanced or metastatic solid tumors? You may be eligible to participate in a advanced or metastatic solid tumors clinical trial.

Recruiting

Male & Female

18 Years +

This study is looking to recruit 316 Participants

W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting its ability to produce a cytotoxic effect. The expected benefits of antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting toxicities of cytotoxic drugs in normal tissues.